Answers are grounded in this paper and cite their sources.
Preclinical study reveals lack of tumor retention by cathepsin B-activatable peptides in tumor models, highlighting limitations for radiotheranostics.
is indicated, this does not contribute to tumor retention as judged from control experiments under pharmacological blockade of cathepsin B and with nonfunctional analogues. The obtained results are discussed in the context of previous data for radiolabeled ACPPs, and limitations for the general use of ACPPs for radiotheranostic approaches are highlighted.
No takes yet. Share an insight, caveat, or question.
Kuhne et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: